Acura Pharmaceuticals
ACUR
ACUR was delisted on the 22nd of February, 2017.
33 hedge funds and large institutions have $19.4M invested in Acura Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 12 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
41% more call options, than puts
Call options by funds: $48K | Put options by funds: $34K
10% more funds holding
Funds holding: 30 → 33 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $22M → $19.4M (-$2.53M)
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
+$92.9K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$65.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$60K |
| 4 |
U
UBS
Zurich,
Switzerland
|
+$36.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$36.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
-$42.2K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$32.1K |
| 3 |
CB
Commerce Bank
Kansas City,
Missouri
|
-$25.4K |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$23K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.8K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| $5K | +$2.05K | +243 | +101% |
|
27
Citigroup
New York
| $4K | -$4.62K | -547 | -55% |
|
28
AllianceBernstein
Nashville,
Tennessee
| $2K | -$17 | -2 | -0.9% |
|
29
Group One Trading
Chicago,
Illinois
| $1K | -$7.77K | -920 | -91% |
|
30
BNP Paribas Financial Markets
Paris,
France
| $120 | +$118 | +14 | New |
|
31
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| $3 | – | – | – |
|
|
CS
32
Credit Suisse
Zurich,
Switzerland
| – | -$23K | -2,436 | Closed |
|
33
State Street
Boston,
Massachusetts
| – | -$20K | -2,126 | Closed |
|
34
Ameriprise
Minneapolis,
Minnesota
| – | -$1.52K | -180 | -93% |
|
|
TDC
35
Thompson Davis & Co
Richmond,
Virginia
| – | +$51 | +6 | New |
|
ACUR Hedge Fund Activity: Q4 2013 in Review
33 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Acura Pharmaceuticals (ACUR) for Q4 2013, worth a combined $19.4M — down 12% from $22M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ACUR positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 12 trimmed.
The largest buyer was Oppenheimer & Co, opening a new position worth an estimated $92.9K. The largest seller was Weiss Multi-Strategy Advisers, cutting an estimated $42.2K.
- 33 institutional investors held Acura Pharmaceuticals (ACUR) as of Q4 2013, up from 30 in Q3 2013.
- Funds reported $19.4M of Acura Pharmaceuticals stock for Q4 2013, down 12% quarter-over-quarter.
- 6 funds opened new Acura Pharmaceuticals positions in Q4 2013 and 3 closed out, a net change of +3 holders.
- The largest Acura Pharmaceuticals buyer in Q4 2013 was Oppenheimer & Co, an estimated $92.9K added.
- The largest Acura Pharmaceuticals seller in Q4 2013 was Weiss Multi-Strategy Advisers, an estimated $42.2K sold.
Based on aggregated 13F filings for Q4 2013.